News
I-Mab (IMAB) stock in focus as the company agrees to buy Bridge Health to secure rights for CLDN18.2 antibody used in its cancer drug, givastomig. Read more here.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback